Rhythm Biosciences Signs Manufacturing Agreement
Filed with ASX · · 3 pages · English
✓ Multi-year commercial supply agreement executed with Quansys Biosciences for ColoSTAT® reagent kit manufacturing. ✓ Agreement provides scalable manufacturing capacity to support ColoSTAT® Access Program and commercial rollout. ✓ Quansys operates ISO13485-certified manufacturing facilities with established quality systems. ✓ Supply partnership reduces manufacturing scale-up and quality system ris
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Quarterly Activities Report and Appendix 4C
- Enhanced Genetype colorectal cancer risk test released - supports earlier disease detection and ColoSTAT® targeting
- datma and Rhythm Biosciences Announce Collaboration to Apply Federated Real-World Data to Genomic Diagnostic Development
- Rhythm Initiates Commercialisation of ColoSTAT
- Appendix 4C and Market Update
Later from Rhythm Biosciences
- ColoSTAT commercial deployment - First physician enrolled
- Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
- Half-Year Financial Report and Appendix 4D
- Trading Halt
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences